Zaklady Farmaceutyczne Polpharma S.A.

An EMIS Company Report EMIS is a Euromoney Institutional Investor plc company USD 29.95 Industry: Pharmaceutical and Medicine Manufacturing Available in: English & Polish Format: PDF Download Most recent financial data: 2016 Buy full report

What’s included?

This report extracts all available information about Zaklady Farmaceutyczne Polpharma S.A. from EMIS' database of company information. The Table of Contents on the right indicates the categories of information that will be included in your report upon purchase.

Download a sample report

Company Tear Sheet (locked content will be provided in the purchased report)

Contact Information

Ul. Pelplinska 19
Starogard Gdanski; Pomorskie; Map
Postal Code: 83-200

Tel: +48 (58) 562, +48 (58) 563
Fax: +48 (58) 562



Company Description
Polpharma is among the 20 largest generics companies in the world, with a turnover of approx. 1 billion dollars a year. It employs more than 7,500 people in Poland and in some foreign markets. The company has 7 production plants in Poland, Russia and Kazakhstan, and 7 centers of research and development. Polpharma Group's portfolio includes about 600 products, and another 200 are under development. Polpharma SA specializes in cardiology, gastroenterology and neurology. A significant part of the product portfolio are the medications available over the counter (OTC). The company offer also includes dietary supplements, medical devices, cosmetics and herbal medicines.
NAICS Industry Classification
Main Activities: Pharmaceutical and Medicine Manufacturing | Drugs and Druggists' Sundries Merchant Wholesalers
Basic Information
Total Employees:
2,146 (2015)
Registered Capital:
Financial Auditors:
Incorporation Date:
August 22, 2002
Profile Updated:
December 20, 2017
Key Executives
Vice President
Vice President
Vice President
Vice President
Ownership Details
Genefar Bv (Netherlands)
Key Financial Highlights
2016 Y
Net sales revenue
Total operating revenue
Operating profit (EBIT)
Net Profit (Loss) for the Period
Total assets 4,106,885
Total equity
Operating Profit (EBIT) Margin
Return on Sales (ROS)
Return on Equity (ROE)
Debt to Equity
Quick Ratio
Cash Ratio
Note: units in Thousands. Statement: Audited, Individual
Financial Performance Charts
Top Competitors

Financial Statements

Annual Statements

EMIS Credit Analytics

EMIS Benchmark Score
Enterprise ACCESS

If you need regular and ongoing access to company information, you should consider a subscription to the full EMIS service.

EMIS company profiles are part of a larger information service where that combines company, industry and country data and analysis for over 125 emerging markets on a unique information platform.


To view more information, REQUEST A DEMO